Pawan Kumar Goel v. Dr. Dhan Singh & Anr.

In the high-stakes world of pharmaceutical innovation, process patents are the invisible engines that drive competitive advantage. But what happens when a patent holder suspects infringement, only to discover that proving the claim requires cracking open the defendant's most guarded commercial secrets? This case presents a fascinating intersection of intellectual property rights, evidentiary challenges, and the delicate balance courts must strike between justice and confidentiality—a lesson every founder handling proprietary processes should understand.

Pawan Kumar Goel, the plaintiff, held a process patent related to the extraction of Alpha Yohimbine, a specialized chemical compound with commercial value in the pharmaceutical and research markets. Believing that Dr. Dhan Singh and another party (the defendants) were manufacturing their product using the very process he had patented, Goel filed a suit seeking a permanent injunction to halt the alleged infringement. The defendants, meanwhile, were operating in the same commercial space and possessed their own proprietary methods and confidential know-how that they were unwilling to disclose publicly.

The legal friction in this case was both procedural and substantive. On one side, the plaintiff argued that the defendants' product could only have been made using his patented extraction process, and he needed access to the defendants' manufacturing details to prove this claim. On the other side, the defendants resisted full disclosure, citing the protection of their own trade secrets and confidential commercial information. The court faced a classic dilemma: how could the plaintiff substantiate his infringement claim without forcing the defendants to reveal sensitive proprietary data that could itself be misused or exposed?

Recognizing the impasse, the court issued an interim order that addressed the evidentiary challenge head-on. Rather than demanding full disclosure or dismissing the plaintiff's claims, the court constituted a confidentiality club—a controlled mechanism allowing designated representatives to review sensitive information under strict confidentiality safeguards. This approach enabled the plaintiff to pursue his infringement claim while protecting the defendants' commercial secrets from public exposure. The interim order reflected the court's commitment to procedural fairness, ensuring that neither party's legitimate interests were sacrificed in the pursuit of justice.

For founders and IP professionals, this case offers a critical lesson: when process patent disputes intersect with trade secrets, the courtroom is not a place for absolute transparency. If you hold a process patent and suspect infringement, be prepared for the reality that proving your claim may require navigating confidentiality protections. Conversely, if you are defending against such claims, understand that courts have tools like confidentiality clubs to balance competing interests. The practical takeaway is to build your IP strategy with both patents and trade secrets in mind, and to anticipate that litigation may require creative procedural solutions rather than straightforward discovery.